CEVEC further strengthens organization to drive industrialization and commercialization of CAP® technologies

  • Life sciences industry veteran Bart Bergstein to join CEVEC’s Supervisory Board
  • Two newly formed Scientific Advisory Boards for CEVEC’s CAP®GT and CAP®Go technologies will further drive industrialization


Cologne, Germany, June 29, 2016

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a strengthening of the Company reflective of its strategic progress.

Bart Bergstein, industry veteran and well-known former life sciences venture capitalist, has been appointed to CEVEC’s Supervisory Board, replacing Rainer Christine, who stepped down for personal reasons.

Bart Bergstein brings over 25 years of experience in finance, executive management and investment in innovative life sciences companies to CEVEC’s Advisory Board. Bart’s career includes milestones such as the establishment of the life sciences venture team within ABN AMRO where he and his team built a portfolio of over EUR 100 million in life sciences investments and realizing multiple highly profitable exits. He co-founded Forbion Capital Partners, a Dutch based venture capital firm managing over EUR 500 million in various funds. High return investments under Bart’s responsibility included Rhein Biotech, Crucell and AM Pharma. Bart also has executive experience as CFO of Cellnovo Group SA where he managed a successful IPO on Euronext Paris.

Bart Bergstein said: “I am looking forward to contributing to the future development of CEVEC and helping to accelerate the Company’s growth. With its outstanding platforms, CEVEC, today, is a very attractive company in the emerging fields of gene therapy vector production and difficult to produce proteins. With many key opportunities ahead of CEVEC, it’s certainly a very exciting time to join the Board.”

Furthermore, CEVEC implements two new Scientific Advisory Boards, which will specifically support the Company to further drive industrialization and commercialization of its proprietary expression platforms; CAP®GT for gene therapy vector production and CAP®Go for glycosylated difficult to produce proteins.

The new CAP®GT Scientific Advisory Board, consisting of Dr. Otto Merten, expert in viral vector production from Généthon, and Prof. Dr. Stefan Kochanek, gene therapy specialist from the University of Ulm, both support the Company by enlarging its knowledgebase and network with respect to the industrial scale CAP®GT derived lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) development and production.

The CAP®Go Board, consisting of Prof. Dr. Thomas Noll, specialist in industrial cell culture technologies from the University of Bielefeld and Prof. Dr. Jürgen Hubbuch, expert in downstream processing of proteins from the Karlsruhe Institute of Technology, are focusing on the industrialization of CAP®Go-based protein manufacturing.

“Our CAP® technologies close gaps created by HEK293 and CHO based production systems regarding industrial viral vector production and manufacturing of proteins previously out of reach,” commented Frank Ubags, Chief Executive Officer of CEVEC Pharmaceuticals GmbH. “By involving internationally recognized experts, we expect to further accelerate the execution of our strategy to set new global standards in biopharmaceutical production. We plan, also, to strengthen our Boards with the further appointment of key industry experts as we further grow and penetrate markets.”

Please follow this link to read the full article.